Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species

BACKGROUND: The aggregation of the protein ɑ-synuclein (ɑS) underlies a range of increasingly common neurodegenerative disorders including Parkinson’s disease. One widely explored therapeutic strategy for these conditions is the use of antibodies to target aggregated ɑS, although a detailed molecula...

Descripción completa

Detalles Bibliográficos
Autores principales: Iljina, Marija, Hong, Liu, Horrocks, Mathew H., Ludtmann, Marthe H., Choi, Minee L., Hughes, Craig D., Ruggeri, Francesco S., Guilliams, Tim, Buell, Alexander K., Lee, Ji-Eun, Gandhi, Sonia, Lee, Steven F., Bryant, Clare E., Vendruscolo, Michele, Knowles, Tuomas P. J., Dobson, Christopher M., De Genst, Erwin, Klenerman, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496350/
https://www.ncbi.nlm.nih.gov/pubmed/28673288
http://dx.doi.org/10.1186/s12915-017-0390-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496350/
https://www.ncbi.nlm.nih.gov/pubmed/28673288
http://dx.doi.org/10.1186/s12915-017-0390-6

Ejemplares similares